To further establish the role of NAV3 in endometrial cancer, we overexpressed EGFP-fused wildtype (EGFPN1-NAV3WT) and mutant (EGFPN1-NAV3D1047N) NAV3 in Ishikawa cells, with the latter being used as functionally inactive negative control. This evidence concerns the gene NAV3 and endometrial cancer.